A new non-surgical medical device is currently undergoing clinical trials in the U.S. for the treatment of type 2 diabetes in patients who are also trying to lose weight. The device constructs a physical barrier between a portion of the intestinal wall and consumed food to adjust hormone release to reduce appetite and control blood sugar.
Unlike other weight reduction procedures, the EndoBarrier is inserted using an endoscope and placed at the start of the small intestine. It lines the first 2ft of the small intestine where the majority of calories are absorbed. The device is reversible and can be left in place for up to one year. In 13 trials of over 1,000 patients completed outside of the U.S., 87% of patients reached their target blood sugar levels and lost an average of 18% of their total body weight after nine months.
The EndoBarrier has already been approved for use in Australia, Europe, and Chile. GI Dynamics is conducting clinical trials in 18 cities across the U.S.
For more information call (888) 978-8399 or visit EndoBarrierTrial.com.